JETEMA Decides on 7 Billion KRW Convertible Preferred Share Third-Party Allotment for Global Product Launch
JETEMA announced the issuance of 1,412,422 voting convertible preferred shares at 4,956 KRW per share via third-party allotment, raising approximately 7 billion KRW.
The proceeds will be used as operating capital for the global launch of JETEMA The Toxin, scheduled for execution from 2027 onwards.
The convertible preferred shares can be converted into common shares from one year after issuance up to five years, with a conversion price of 4,956 KRW, which represents a premium over the current market price. The potential dilution upon full conversion is approximately 3.79% relative to total outstanding shares.
The shares carry preferential dividend rights with cumulative and participating features and are subject to a one-year lock-up period.
The third-party allocatees include funds managed by major domestic securities firms such as Mirae Asset Securities, KB Securities, and NH Investment & Securities, indicating high counterparty credibility.
No separate shareholder return policies such as treasury stock acquisition, cancellation, or dividend changes were disclosed.
[AI Summary]JETEMA is issuing approximately 7 billion KRW in convertible preferred shares to fund a global product launch. The moderate dilution of 3.79% and the premium issuance price limit short-term shareholder value erosion, but the potential downward adjustment of conversion price and preferred dividend obligations pose risks. Institutional participation ensures funding stability, but a neutral view is warranted as the funds are allocated to growth investments rather than covering operating losses.
KOSDAQ Filing Information
Report On Major Matters (Decision On Paid-In Capital Increase)